Novocure to Report Second Quarter 2024 Financial Results
01 July 2024 - 9:00PM
Business Wire
Novocure (NASDAQ: NVCR) announced today that it will report
financial results for the second quarter 2024 on Thursday, July 25,
2024, before the U.S. financial markets open. Novocure management
will host a conference call and webcast to discuss the company’s
financial results for the three and six months ended June 30, 2024,
at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the
conference call by phone, use the following conference call
registration link and dial-in details will be provided. To access
the webcast, use the following webcast registration link.
The slides presented during the webcast and the corporate
presentation can be accessed live from the Investor Relations page
of Novocure’s website, www.novocure.com/investor-relations, and
will be available for at least 14 days following the call. Novocure
has used, and intends to continue to use, its investor relations
website as a means of disclosing material non-public information
and for complying with its disclosure obligations under Regulation
FD.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical studies
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical study progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “could” “anticipate,” “estimate,” “expect,”
“project,” “intend,” “plan,” “believe” or other words and terms of
similar meaning. Novocure’s performance and financial results could
differ materially from those reflected in these forward-looking
statements due to general financial, economic, environmental,
regulatory and political conditions and other more specific risks
and uncertainties facing Novocure such as those set forth in its
Annual Report on Form 10-K filed on February 22, 2024, and
subsequent filings with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701586779/en/
Investors and Media: Ingrid Goldberg
investorinfo@novocure.com media@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Sep 2024 to Oct 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Oct 2023 to Oct 2024